IMpower132: PFS and Safety Results with 1L Atezolizumab plus Carboplatin/Cisplatin plus Pemetrexed in Stage IV Non-Squamous NSCLC

Simple item page
dc.contributor.authorPapadimitrakopoulou, V.
dc.contributor.authorCobo, M.
dc.contributor.authorBordoni, R.
dc.contributor.authorDubray-Longeras, P.
dc.contributor.authorSzalai, Z.
dc.contributor.authorUrsol, G.
dc.contributor.authorNovello, S.
dc.contributor.authorOrlandi, F.
dc.contributor.authorBall, S.
dc.contributor.authorGoldschmidt, J., Jr.
dc.contributor.authorSanborn, R.
dc.contributor.authorHoang, T.
dc.contributor.authorMendus, D.
dc.contributor.authorDeng, Y.
dc.contributor.authorKowanetz, M.
dc.contributor.authorWen, X.
dc.contributor.authorLin, W.
dc.contributor.authorSandler, A.
dc.contributor.authorNishion, M.
dc.contributor.authoraffiliation[Papadimitrakopoulou, V.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
dc.contributor.authoraffiliation[Cobo, M.] Hosp Univ Malaga Reg, Ibima, Malaga, Spain
dc.contributor.authoraffiliation[Bordoni, R.] Northside Hosp Canc Inst, Marietta, GA USA
dc.contributor.authoraffiliation[Dubray-Longeras, P.] Ctr Jean Perrin, Clermont Ferrand, France
dc.contributor.authoraffiliation[Szalai, Z.] Petz Aladar Cty Teaching Hosp, Pulmonol, Gyor, Hungary
dc.contributor.authoraffiliation[Ursol, G.] Acinus, Kirovograd, Ukraine
dc.contributor.authoraffiliation[Novello, S.] Univ Turin, Turin, Italy
dc.contributor.authoraffiliation[Orlandi, F.] Inst Nacl Torax, Santiago, Chile
dc.contributor.authoraffiliation[Ball, S.] Queens Hosp, Romford, Essex, England
dc.contributor.authoraffiliation[Goldschmidt, J., Jr.] Blue Ridge Canc Care, Blacksburg, VA USA
dc.contributor.authoraffiliation[Sanborn, R.] Providence Portland Med Ctr, Portland, OR USA
dc.contributor.authoraffiliation[Hoang, T.] Genentech Inc, San Francisco, CA 94080 USA
dc.contributor.authoraffiliation[Mendus, D.] Genentech Inc, San Francisco, CA 94080 USA
dc.contributor.authoraffiliation[Deng, Y.] Genentech Inc, San Francisco, CA 94080 USA
dc.contributor.authoraffiliation[Kowanetz, M.] Genentech Inc, San Francisco, CA 94080 USA
dc.contributor.authoraffiliation[Wen, X.] Genentech Inc, San Francisco, CA 94080 USA
dc.contributor.authoraffiliation[Lin, W.] Genentech Inc, San Francisco, CA 94080 USA
dc.contributor.authoraffiliation[Sandler, A.] Genentech Inc, San Francisco, CA 94080 USA
dc.contributor.authoraffiliation[Nishion, M.] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
dc.date.accessioned2025-01-07T16:37:25Z
dc.date.available2025-01-07T16:37:25Z
dc.date.issued2018-10-01
dc.identifier.doi10.1016/j.jtho.2018.08.262
dc.identifier.essn1556-1380
dc.identifier.issn1556-0864
dc.identifier.unpaywallURLhttp://www.jto.org/article/S1556086418312206/pdf
dc.identifier.urihttps://hdl.handle.net/10668/27903
dc.identifier.wosID454014500246
dc.issue.number10
dc.issue.numberS
dc.journal.titleJournal of thoracic oncology
dc.journal.titleabbreviationJ. thorac. oncol.
dc.language.isoen
dc.organizationInstituto de Investigación Biomédica de Málaga - Plataforma Bionand (IBIMA)
dc.page.numberS332-S333
dc.publisherElsevier science inc
dc.rights.accessRightsopen access
dc.subjectatezolizumab
dc.subject1L NSCLC
dc.subjectchemotherapy
dc.titleIMpower132: PFS and Safety Results with 1L Atezolizumab plus Carboplatin/Cisplatin plus Pemetrexed in Stage IV Non-Squamous NSCLC
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number13
dc.wostypeMeeting Abstract

Files

Collections

Instituto de Investigación Biomédica de Málaga - Plataforma Bionand (IBIMA)

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía